239 related articles for article (PubMed ID: 30639168)
1. Multimodal dopaminergic and free-water imaging in Parkinson's disease.
Yang J; Archer DB; Burciu RG; Müller MLTM; Roy A; Ofori E; Bohnen NI; Albin RL; Vaillancourt DE
Parkinsonism Relat Disord; 2019 May; 62():10-15. PubMed ID: 30639168
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
Bohnen NI; Albin RL; Koeppe RA; Wernette KA; Kilbourn MR; Minoshima S; Frey KA
J Cereb Blood Flow Metab; 2006 Sep; 26(9):1198-212. PubMed ID: 16421508
[TBL] [Abstract][Full Text] [Related]
4. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
[TBL] [Abstract][Full Text] [Related]
5. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
6. Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
Burciu RG; Ofori E; Archer DB; Wu SS; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
Brain; 2017 Aug; 140(8):2183-2192. PubMed ID: 28899020
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of
Sanchez-Catasus CA; Bohnen NI; Yeh FC; D'Cruz N; Kanel P; Müller MLTM
J Nucl Med; 2021 Apr; 62(4):545-552. PubMed ID: 32859707
[TBL] [Abstract][Full Text] [Related]
8. [18F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease.
Juri C; Kramer V; Riss PJ; Soza-Ried C; Haeger A; Pruzzo R; Rösch F; Amaral H; Chana-Cuevas P
Clin Nucl Med; 2021 Feb; 46(2):119-124. PubMed ID: 33323728
[TBL] [Abstract][Full Text] [Related]
9. Free-water imaging in Parkinson's disease and atypical parkinsonism.
Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
[TBL] [Abstract][Full Text] [Related]
11. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
[TBL] [Abstract][Full Text] [Related]
12. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease.
Martin WR; Wieler M; Stoessl AJ; Schulzer M
Ann Neurol; 2008 Mar; 63(3):388-94. PubMed ID: 18240153
[TBL] [Abstract][Full Text] [Related]
13. Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.
Bohnen NI; Müller ML; Zarzhevsky N; Koeppe RA; Bogan CW; Kilbourn MR; Frey KA; Albin RL
Brain; 2011 Aug; 134(Pt 8):2358-65. PubMed ID: 21653540
[TBL] [Abstract][Full Text] [Related]
14. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
[TBL] [Abstract][Full Text] [Related]
15. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
Song IU; Chung YA; Oh JK; Chung SW
Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
[TBL] [Abstract][Full Text] [Related]
17. Constipation Increases Disability and Decreases Dopamine Levels in the Nigrostriatal System through Gastric Inflammatory Factors in Parkinson's Disease.
Zhou Y; Su Y; Xu W; Wang W; Yao S
Curr Neurovasc Res; 2019; 16(3):241-249. PubMed ID: 31258082
[TBL] [Abstract][Full Text] [Related]
18. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
Koeppe RA; Gilman S; Junck L; Wernette K; Frey KA
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
[TBL] [Abstract][Full Text] [Related]
19. Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease.
Delva A; Van Weehaeghe D; Koole M; Van Laere K; Vandenberghe W
Mov Disord; 2020 Nov; 35(11):1977-1986. PubMed ID: 32767618
[TBL] [Abstract][Full Text] [Related]
20. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
